Dehydronorketamine

Dehydronorketamine
Systematic (IUPAC) name
6-Amino-6-(2-chlorophenyl)cyclohex-2-en-1-one
Identifiers
CAS Number 57683-62-2
ATC code None
PubChem CID 162835
ChemSpider 142954
Chemical data
Formula C12H12ClNO
Molar mass 221.68278 g/mol

Dehydronorketamine (DHNK), or 5,6-dehydronorketamine, is a minor metabolite of ketamine which is formed by dehydrogenation of its metabolite norketamine.[1][2] Though originally considered to be inactive,[1][2][3] DHNK has been found to act as a potent and selective negative allosteric modulator of the α7-nicotinic acetylcholine receptor (IC50 = 55 nM).[4][5] For this reason, similarly to hydroxynorketamine, it has been hypothesized that DHNK may have the capacity to produce rapid antidepressant effects.[6] However, unlike ketamine and norketamine, DHNK has been found to be inactive in the forced swim test (FST) in mice at doses up to 50 mg/kg, likely due to its far lower potency as an NMDA receptor antagonist in comparison.[7] DHNK is inactive at the α3β4-nicotinic acetylcholine receptor (IC50 > 100 μM) and is only very weakly active at the NMDA receptor (Ki = 38.95 μM for (S)-(+)-DHNK).[4] It can be detected 7–10 days after a modest dose of ketamine, and because of this, is useful in drug detection assays.[8]

See also

References

  1. 1 2 Bruno Bissonnette (14 May 2014). Pediatric Anesthesia. PMPH-USA. pp. 366–. ISBN 978-1-60795-213-8.
  2. 1 2 J. John Mann (9 May 2013). Clinical Handbook for the Management of Mood Disorders. Cambridge University Press. pp. 347–. ISBN 978-1-107-06744-8.
  3. ↑ The Neuropsychiatric Complications of Stimulant Abuse. Elsevier Science. 1 June 2015. pp. 225–. ISBN 978-0-12-803003-5.
  4. 1 2 Moaddel, Ruin; Abdrakhmanova, Galia; Kozak, Joanna; Jozwiak, Krzysztof; Toll, Lawrence; Jimenez, Lucita; Rosenberg, Avraham; Tran, Thao; Xiao, Yingxian; Zarate, Carlos A.; Wainer, Irving W. (2013). "Sub-anesthetic concentrations of (R,S)-ketamine metabolites inhibit acetylcholine-evoked currents in α7 nicotinic acetylcholine receptors". European Journal of Pharmacology 698 (1-3): 228–234. doi:10.1016/j.ejphar.2012.11.023. ISSN 0014-2999.
  5. ↑ Robin A.J. Lester (11 November 2014). Nicotinic Receptors. Springer. pp. 445–. ISBN 978-1-4939-1167-7.
  6. ↑ Paul, Rajib K.; Singh, Nagendra S.; Khadeer, Mohammed; Moaddel, Ruin; Sanghvi, Mitesh; Green, Carol E.; O’Loughlin, Kathleen; Torjman, Marc C.; Bernier, Michel; Wainer, Irving W. (2014). "(R,S)-Ketamine Metabolites (R,S)-norketamine and (2S,6S)-hydroxynorketamine Increase the Mammalian Target of Rapamycin Function". Anesthesiology 121 (1): 149–159. doi:10.1097/ALN.0000000000000285. ISSN 0003-3022. PMID 24936922.
  7. ↑ Sałat K, Siwek A, Starowicz G, Librowski T, Nowak G, Drabik U, et al. (2015). "Antidepressant-like effects of ketamine, norketamine and dehydronorketamine in forced swim test: Role of activity at NMDA receptor". Neuropharmacology 99: 301–7. doi:10.1016/j.neuropharm.2015.07.037. PMID 26240948.
  8. ↑ Q. Alan Xu (1 April 2013). Ultra-High Performance Liquid Chromatography and Its Applications. John Wiley & Sons. pp. 1–. ISBN 978-1-118-53398-7.


This article is issued from Wikipedia - version of the Tuesday, April 05, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.